212 related articles for article (PubMed ID: 9030717)
41. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
42. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
43. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
Behrendt N; Danø K
FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
[TBL] [Abstract][Full Text] [Related]
44. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
45. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin.
Dumler I; Stepanova V; Jerke U; Mayboroda OA; Vogel F; Bouvet P; Tkachuk V; Haller H; Gulba DC
Curr Biol; 1999 Dec 16-30; 9(24):1468-76. PubMed ID: 10607589
[TBL] [Abstract][Full Text] [Related]
46. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
[TBL] [Abstract][Full Text] [Related]
47. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
48. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
49. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
50. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
51. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
52. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.
Rajagopal V; Kreitman RJ
J Biol Chem; 2000 Mar; 275(11):7566-73. PubMed ID: 10713063
[TBL] [Abstract][Full Text] [Related]
53. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.
Rasch MG; Lund IK; Almasi CE; Hoyer-Hansen G
Front Biosci; 2008 May; 13():6752-62. PubMed ID: 18508692
[TBL] [Abstract][Full Text] [Related]
54. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
Shetty S; Kumar A; Johnson AR; Pueblitz S; Holiday D; Raghu G; Idell S
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):78-87. PubMed ID: 8679225
[TBL] [Abstract][Full Text] [Related]
55. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Baker MS; Liang XM; Doe WF
Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
[TBL] [Abstract][Full Text] [Related]
56. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
57. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway.
Oka H; Kugiyama K; Doi H; Matsumura T; Shibata H; Miles LA; Sugiyama S; Yasue H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):244-50. PubMed ID: 10634825
[TBL] [Abstract][Full Text] [Related]
58. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
Montuori N; Salzano S; Rossi G; Ragno P
FEBS Lett; 2000 Jul; 476(3):166-70. PubMed ID: 10913606
[TBL] [Abstract][Full Text] [Related]
59. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor.
Andolfo A; English WR; Resnati M; Murphy G; Blasi F; Sidenius N
Thromb Haemost; 2002 Aug; 88(2):298-306. PubMed ID: 12195704
[TBL] [Abstract][Full Text] [Related]
60. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]